At last, a RE-LYable alternative to warfarin for atrial fibrillation

International Journal of Stroke

Volumn 4, Issue 6, 2009, Pages 454-455

  Hankey, G J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Anticoagulation; Atrial fibrillation; Dabigatran etexilate; RE LY trial; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE; WARFARIN;

ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; DYSPEPSIA; HEART ATRIUM FIBRILLATION; HUMAN; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; DYSPEPSIA; HEMORRHAGE; HUMANS; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WARFARIN;

EID: 77449106972     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2009.00389.x     Document Type: Note

References (5)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-67.
2. Diener H-C., and the Executive Steering Committee on behalf of the SPORTIF III and V Investigators Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21:279-93.
3. AMADEUS Investigators, Bousser MG, Bouthier J et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation - a randomised, open-label, non-inferiority trial. Lancet 2008; 371:315-21.
4. Connolly SJ, Ezekowitz MD, Yusuf S et al., and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-51.
5. Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Therapeutics 2009; 86:139-46.